Clinical trial

PROBE Investigation of the Safety & Efficacy of Telmisartan (Micardis®) vs…

NCT00274599 · Boehringer Ingelheim, Industry · Completed

Key facts

NCT number NCT00274599
Title PROBE Investigation of the Safety & Efficacy of Telmisartan (Micardis®) vs Ramipril (Altace®) Using ABPM in HTN
Official title A Prospective, Randomised, Open-Label, Blinded-Endpoint, Parallel Group, Multicentre, Forced-Titration, 14-Week Treatment Study Comparing MICARDIS® (Telmisartan 40-80-80 mg, QD) and ALTACE® (Ramipril 2.5-5-10 mg, QD) in Patients With Mild-to-Moderate Hypertension Using Ambulatory Blood Pressure…
Lead sponsor Boehringer Ingelheim, Industry
Status Completed
Phase Phase 4
Study type Interventional
Conditions Hypertension
Intervention type Drug
Interventions Telmisartan, Ramipril
Enrollment 812
Start date Oct 9, 2002
Primary completion Nov 30, 2003
First posted Jan 11, 2006
Last update posted Dec 6, 2023
Countries Canada, United States

At a glance

  • 10–99 Study sites
  • No Results posted
  • None Linked FDA submissions

Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.

About ClinicalTrials.gov studies

ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.

Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date:

Browse all ClinicalTrials.gov studies